DAX24.340 +0,2%Est505.749 ±0,0%MSCI World4.343 -0,1%Top 10 Crypto11,38 -1,7%Nas23.562 +0,6%Bitcoin74.087 ±-0,0%Euro1,1791 ±-0,0%Öl62,49 +0,1%Gold4.491 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 DroneShield A2DMAA Rheinmetall 703000 Lufthansa 823212 Deutsche Telekom 555750 Bayer BAY001 Allianz 840400 Tesla A1CX3T D-Wave Quantum A3DSV9 Infineon 623100 Amazon 906866 Siemens Energy ENER6Y Deutsche Bank 514000 TUI TUAG50
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Tesla-Aktie: Holiday Update bringt verbesserte Fahrzeug-Lokalisierung Tesla-Aktie: Holiday Update bringt verbesserte Fahrzeug-Lokalisierung
Erste Group Bank-Aktie: Santander-Töchter in Polen darf übernommen werden Erste Group Bank-Aktie: Santander-Töchter in Polen darf übernommen werden
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Intensity Therapeutics Aktie

Kaufen
Verkaufen
0,4138 USD -0,0003 USD -0,07 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.21,25 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3C9BX

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45828J1034

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolINTS

Intensity Therapeutics Aktien News

DatumMeistgelesen
PR NewswireIntensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
PR NewswireIntensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
PR NewswireIntensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
PR NewswireIntensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
PR NewswireIntensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
PR NewswireIntensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
PR NewswireIntensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
PR NewswireIntensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
PR NewswireIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
PR NewswireIntensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INV...
PR NewswireIntensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
PR NewswireIntensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treat...
PR NewswireIntensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 ...
PR NewswireIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
PR NewswireDrug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR NewswireIntensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
PR NewswireIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the O...
PR NewswireIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2...
PR NewswireIntensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
PR NewswireIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Tr...
PR NewswireIntensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireIntensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
PR NewswireIntensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
PR NewswireIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Eu...
PR NewswireIntensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
PR NewswireIntensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
PR NewswireIntensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
PR NewswireIntensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
PR NewswireIntensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
PR NewswireIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
PR NewswireIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Intensity Therapeutics News

Intensity Therapeutics News: auf dieser Seite finden Sie alle Intensity Therapeutics News und Nachrichten zur Intensity Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Intensity Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Intensity Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.